跳至主要内容
临床试验/IRCT20230801059005N2
IRCT20230801059005N2招募中3 期

Evaluation of the effect of Ranolazine added to standard treatment to control angina pectoris in patients with coronary artery bridge who underwent angiography in Alzahra Heart Hospital, Shiraz during 2023 and 2024

Shiraz University of Medical Sciences0 个研究点目标入组 52 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
52

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Iranian origin
  • No history of organ damage, heart failure or renal failure
  • Willingness to participate in research
  • Angina or dyspnea on exertion or at rest
  • No coronary artery disease (less than 50% stenosis in all epicardial coronary arteries)

排除标准

  • Not willing to keep participating in the trial
  • patients younger than 18 years
  • Liver failure, long QT, renal failure
  • Using CYP3A inhibitors such as Diltiazem, Verapamil, Ketoconazole, Macrolides and protease inhibitors
  • Patient who are using medication that cause QT prolongation
  • Pregnancy or lactation
  • Parkinson's disease
  • Life expectancy less than 6 months

研究者

相似试验